Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels

Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels

Takeda Pharmaceutical’s oveporexton is designed to treat the root cause of narcolepsy. Statistically significant Phase 3 results for the twice daily pill were presented Monday during the World Sleep 2025 Congress in Singapore. The post Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels appeared first on MedCity News.

Alkermes, Takeda show encouraging data on narcolepsy drugs

The companies are hopeful that a new class of medicines can eventually treat sleepiness tied to a wide range of conditions.

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 8, 2025-

Takeda’s Phase 3 narcolepsy results could make it first mover in multibillion-dollar market

Takeda met all endpoints in two Phase 3 trials of its orexin agonist oveporexton in narcolepsy type 1, bringing the Japanese drugmaker a step closer to a market that Wall Street says could generate sales of over $9 billion.